C-T581Cyclone Therapeutics
Trappsol Cyclo, rare neurological disorders
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-T581
C-T581C-T581Trappsol Cyclo, rare neurological disorders
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Cyclone Therapeutics Trappsol Cyclo, rare neurological disorders
Cyclo Therapeutics is dedicated to developing medicines for patients and families living with rare and neurological disorders. The website highlights Trappsol Cyclo, a pipeline focused on Niemann-Pick Disease Type C and Alzheimer's Disease, and the TransportNPC Phase 3 study in Niemann-Pick Disease Type C. The footer identifies the company as "Cyclo Therapeutics, LLC, A Rafael Company."
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Cyclone Therapeutics — Near-term readout · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic